Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)

Background: About a third of patients with inflammatory bowel disease (IBD) do not respond to anti-tumor necrosis factor (anti-TNF) therapy. In our study, we evaluated the effectiveness of vedolizumab and ustekinumab in achieving clinical and endoscopic outcomes in anti-TNF-experienced patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Alrashed, Fatema, Abdullah, Israa, Alfadhli, Ahmad, Shehab, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590879/
https://www.ncbi.nlm.nih.gov/pubmed/37876726
http://dx.doi.org/10.3389/fphar.2023.1243080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590879/
https://www.ncbi.nlm.nih.gov/pubmed/37876726
http://dx.doi.org/10.3389/fphar.2023.1243080

Ejemplares similares